)
Bafna Pharmaceuticals Ltd, a Chennai-based pharma company, today informed the BSE that it has received approval from Ghana Food and Drug Administration (FDA) to market Omeran-20 capsules (Gastro-Resistant Omerprazole Capsules 20mg).
The capsules are proton pump inhibitors used in the treatment of reflux oesophagitis, peptic ulcer disease (PUD), Gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome.
Mahaveer Bafna, CMD, Bafna Pharmaceuticals Ltd said that the approval will strengthen the company's presence in Ghana and help them penetrate their target market segment.
The drug contains generic salt - Omeprazole - and its International Classification of Diseases is Omeprazole.
With this, Bafna now has 15 formulation approvals from Ghana FDA.
